merck 3rd qtr sales of isentress just released yesterday
ISENTRESS (raltegravir), Merck's first-in-class HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, reported worldwide sales of $197 million for the third quarter of 2009, an increase of 84 percent compared with the third quarter 2008.
so we have for the nrti sales
ftc 2.4B tdf 2.6B 3tc 1.0B atc ???
and catching up with next year >$1B
isentress 0.8B
AVX Price at posting:
19.0¢ Sentiment: LT Buy Disclosure: Held